ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

Former NIH Director Varmus calls for more oversight of conflicts, expresses surprise at growth of Title 42 program.

May 21, 2004

ODAC Okays First “Paper NDA,” By BMS For Bieomycin

October 1, 1993

NCI Diet Guideline Outlined At Senate Hearing

November 22, 1985

NCI To Slow New Center Development To Assure Funding For Existing Commitments, King Says

February 14, 1975

In Brief: Online Genetics Glossary; ORI Misconduct Finding

February 5, 1999

H. Lee Moffitt Center Reads The Cancer Letter

July 19, 2002